Article
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.
Journal of gastroenterology and hepatology - 1 Mar 2021
Ji Fanpu, Li Jie, Liu Li, Liang Jing, Wang Xiaozhong, Liu Junping, Cai Dachuan, Huang Rui, Zhang Jiajie, Wang Qi, Nan Yuemin, Li Junyi, Ye Qing, Zhang Mingyuan, Xu Qiang, Guo Feng, Zhao Changqing, Liu Lingdi, He Caini, Li Yu, Wang Wenjun, Kam Leslie Y, Tran Sally, Maeda Mayumi, Mizuta Akiko, Li Zongfang, Dang Shuangsuo, Ren Wanhua, Zhu Qiang, Cheung Ramsey, Niu Junqi, Xie Wen, Pan Hongying, Ren Hong, Wu Chao, Shang Jia, Wang Fengmei, Nguyen Mindie H
Abstract excerpt
BACKGROUND AND AIM: Globally, China has the highest chronic hepatitis C (CHC) burden, but its real-world direct-acting antiviral (DAA) data are limited. Our aim is to investigate the real-world outcome of China Food and Drug Administration-approved DAA therapies across mainland China including those with genotype (GT) 3. METHODS: The REAL-C is a multinational real-world interferon-free DAA-treated CHC registry of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.